@DentsplySirona hosts their investor day with a goal to grow earnings at a 15% CAGR between 2023-2026 through streamlining and leveraging its digital assets for growth. #XRAY#investorday
https://t.co/l6Iy3ZBMxf
@QIAGEN launches new digital PCR tests for cell/gene therapy, DNA/RNA quantification, and food safety on its QIAcuity system. #QGEN#diagnostics
https://t.co/XcomKNigdc
@ExagenInc announces a new agreement with Johns Hopkins to license biomarkers for development of a lupus nephritis diagnostic test. #XGN#diagnostics#lupus
https://t.co/0RtMnS5Qg4
@Hologic posts solid 3Q23 results as microprocessor shortages drive a backlog in mammography systems and non-COVID-19 diagnostic growth remains strong. #HOLX#mammography#earnings
https://t.co/R8DqHPyBN6
@illumina posted a challenging 3Q23, but its post-GRAIL profitability could start to make it a target for value focused investors or acquirers. #ILMN#earnings#Genomics
https://t.co/h3A922SOS4
@Natera posted a strong 3Q23 and raised their full year outlook with a number of pending catalysts such as potential Medicare reimbursement for Renasight and continued growth of their leading MRD franchise. #NTRA#earnings#diagnostics#MRD
https://t.co/cnmHAFYGMT
@Invitae's loss increases and revenue declines in the 3Q23 increasing concerns around liquidity and the sustainability of the company. #NVTA#earnings#Genomics
https://t.co/8w7v1kA9sG
New data from ASTRO shows SBRT could be highly effective at treating localize kidney cancer. Positive for radiation therapy providers such as @Accuray. #ARAY#radiationtherapy#kidneycancer
https://t.co/9jnb6ELwfr
Oxford Nanopore has acquired Norther Nanopore Instruments to boost its solid state nanopore development program which could allow detection of multiple biological molecules such as DNA, RNA, metabolites, and proteins. #sequencing#lifescience#nanopore
https://t.co/WZUoaKN4YT
COMBINEDBrain has started a new study to expedite cures for neurodevelopmental disorders by providing whole genome sequencing (WGS) to infants displaying early symptoms of rare genetic neurodevelopmental disorders. #WGS#sequencing
https://t.co/ilxLcsRTpM
@owletmedical receives FDA approval for its wearable Dream Sock baby monitor without a prescription opening it back up to the market following a previous FDA warning letter. #OWLT#wearables#pediatrics
https://t.co/a9WtbrI3jL
@23andMe revenue declines and losses increase in 3Q23 - management is trying to increase price/breadth of service offerings and reduce cost to reduce cash burn but the business is heavily dependent on DTC advertising. #ME#earnings#consumergenetics
https://t.co/JMnN0dDHAd
@ultromics has received a HOPPS code for its heart failure detection technology following IPPS reimbursement earlier this year. Likely to drive increased adoption. #heartfailure#reimbursement
https://t.co/CfnKWmMlJj
@neuronetics magnetic stimulation therapy for depression saw a bunch of payers lower the number of medication failures before coverage is approved. #STIM#depression#reimbursement
https://t.co/QhOLlmdfT2
Medicare has crosswalked the code for Aspira Womens' Health new OvaWatch test to the old code ensuring continuity of reimbursement. #AWH#ovariancancer
https://t.co/0Bxhngw7RV
@orasure beats estimates in the 3Q23, investors are looking for the next act after the company's InteliSwab COVID-19 test to drive growth. #OSUR#COVID19#earnings
https://t.co/lJQWPDXu0N
@AdaptiveBiotech announces a new MRD partnership with leukemia drug maker Beigene for its clonoSEQ assay for MRD assessment in bone marrow. #ADPT#MRD#leukemia
https://t.co/5TETvMNnNH